Immutep (IMMP) Enterprise Value (2011 - 2025)
Immutep's (IMMP) quarterly Enterprise Value came in at -$65.1 million in Q4 2025, up 37.51% YoY from -$47.3 million in Q4 2024, and up 21.64% on a QoQ basis from -$83.1 million in Q2 2025.
Immutep (IMMP) Enterprise Value (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Enterprise Value data on file, last reported at -$65.1 million in Q4 2025.
- Quarterly Enterprise Value rose 37.51% year-over-year to -$65.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$65.1 million (up 37.51% YoY) and the FY2025 annual result came in at -$83.1 million, up 22.1% from the prior year.
- Enterprise Value rose to -$65.1 million in Q4 2025, from -$83.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$44.9 million in Q4 2022 to a low of -$106.6 million in Q2 2024.
- A 5-year average of -$73.0 million and a median of -$70.1 million in 2021 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value sank 170.46% — and 2022, when it soared 38.12%.
- Tracing IMMP's Enterprise Value over 5 years: stood at -$72.6 million in 2021, then surged by 38.12% to -$44.9 million in 2022, then slumped by 50.32% to -$67.5 million in 2023, then sank by 54.23% to -$104.1 million in 2024, then soared by 37.51% to -$65.1 million in 2025.
- The last three Enterprise Value figures came in at -$65.1 million (Q4 2025), -$83.1 million (Q2 2025), and -$104.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | Immutep | 55.96 Mn | -9.12 Mn | - | -65.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.09 Mn |
| Jun 30, 2025 | -83.06 Mn |
| Dec 31, 2024 | -104.15 Mn |
| Jun 30, 2024 | -106.62 Mn |
| Dec 31, 2023 | -67.53 Mn |
| Jun 30, 2023 | -82.49 Mn |
| Dec 31, 2022 | -44.92 Mn |
| Jun 30, 2022 | -57.30 Mn |
| Dec 31, 2021 | -72.60 Mn |
| Jun 30, 2021 | -46.66 Mn |
| Dec 31, 2020 | -40.11 Mn |
| Jun 30, 2020 | -17.25 Mn |
| Dec 31, 2019 | -14.02 Mn |
| Jun 30, 2019 | -11.61 Mn |
| Dec 31, 2018 | -18.65 Mn |
| Jun 30, 2018 | -17.77 Mn |
| Jun 30, 2017 | -9.19 Mn |
| Mar 31, 2017 | -10.51 Mn |
| Jun 30, 2016 | -15.59 Mn |
| Jun 30, 2015 | -5.26 Mn |